Press

Press releases
Press releases

Calmark enters into cooperation with VIA Global Health to accelerate globalization

Calmark Sweden AB today announced that an agreement regarding distribution of the Company's products has been signed with the U.S. company VIA Global Health, which specializes in distribution of medical devices in low- and middle-income countries. The agreement entails that Calmark's products can reach out to countries in, e.g., Africa and South America sooner than anticipated, and more cost-efficiently.
Read more
Press releases

Calmark signs distributor agreement in Italy

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with P.R.I.S.M.A. Srl (Prisma) in Italy. The agreement covers Calmark's test for assessment of COVID-19 disease severity and contains a minimum contract volume of EUR 457 500. The test, "Calmark COVID-19-LDH", is under development and is projected to obtain its CE mark approval during the first quarter of 2021, after which it will be ready for sale.
Read more
Press releases

Calmark Sweden AB locates Chinese mainland office to Wuxi, outside Shanghai

Calmark Sweden AB today announced that a new decision has been made regarding the location of the Company's office in mainland China. Following financial negotiations, the alternative to locate the office to Wuxi, outside Shanghai, appears more advantageous than the previously disclosed location, the Greater Bay Area.
Read more
News

Calmark presents at Redeye Life Science Day 2020

Calmark attends the digital event Redeye Life Science Day 2020 that will be held on November 26. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 9:30. The presentation is held in Swedish and will be broadcast live.
Read more
News

Redeye publishes initial coverage on Calmark

Analyst firm Redeye has today published the report "Calmark: Diagnosing the New Generation".
Read more
News

Calmark recruits Michael Lund to key position as QA/RA Director

Calmark Sweden AB has hired Michael Lund who will assume position as Quality Assurance and Regulatory Affairs Director, a role which he has held on a consultancy basis since 2016. Michael is part of Calmark's management team and is responsible for project management and quality assurance of the product development, as well as certification and registration of the products in different markets.
Read more

Calmark receives order from Triolab Finland

Calmark Sweden AB has today received an order for the Calmark Neo platform, comprising Calmark's instrument as well as tests for bilirubin. The order was placed by Triolab Oy, which is Calmark's exclusive distributor in Finland, Lithuania, Latvia and Estonia.
Read more
Press releases

Calmark receives order from Triolab Finland - clarification

Clarification: Calmark Sweden AB's press release from today at 14:00 regarding order from Triolab Finland is of strategic importance as it shows that Calmark's distributor has now started demonstrations and active sales work. The economic value of the order is of minor importance.
Read more
News

Calmark's subsidiary in Hong Kong is now registered

Calmark Sweden AB today announces that the Company's subsidiary in Hong Kong has been registered. Calmark Hongkong Limited is a wholly-owned subsidiary of the Swedish company. The effort to establish a subsidiary in mainland China continues.
Read more
News

Calmark decides to locate the Chinese subsidiary in Guangzhou, Greater Bay Area

An exploratory review has led Calmark to the conclusion that the Greater Bay Area will be the most suitable location for Calmark's subsidiary in mainland China. The city of Guangzhou, situated as it is and harboring a cluster of MedTech companies, has now been selected for the next phase.
Read more

Calmark receives its first order from Triolab AB in Sweden

Calmark Sweden AB has today received the Company's first order for the Calmark Neo platform. The order covers both the reader and test cassettes for bilirubin, and was placed by Triolab AB, which is Calmark's exclusive distributor in Sweden.
Read more
Press releases

Calmark signs distributor agreement in Jordan

Calmark Sweden AB has today signed an exclusive distributor agreement with the company Alpha Tech Est. in Amman, Jordan.
Read more
Press releases

Calmark's LDH test for assessment of COVID-19 disease severity is estimated to be ready for launch in Q1 2021

Calmark Sweden AB announces today that the product development of an LDH test for assessment (triage) of COVID-19 is proceeding according to plan; the test is now projected to obtain CE conformity marking in Q1 2021. The project has now successfully completed the chemical impregnation in Calmark's recently installed BioDot machine, which will be used in the production line.
Read more
Press releases

Calmark Sweden is granted two new patents

Calmark Sweden AB has been granted two new patents, one concerning the technical construction of the single-use item and one concerning the method of reading bilirubin. These will be published in the Swedish Patent Gazette No. 2020/39, on 2020-09-22. The patents are numbered 543 001 and 543 002.
Read more
News

Calmark recruits Jim Hansson for the role as Director of Production & Logistics

Calmark Sweden AB has hired Jim Hansson who will assume position as Director of Production & Logistics. Jim will be responsible for the development of Calmark's production and logistics, and will take office in October 2020.
Read more
News

Calmark hires Camilla Arneving as Marketing Director

Calmark Sweden AB has recruited Camilla Arneving for the role as Marketing Director, a position that she has held on an interim basis for almost two years. Camilla is part of Calmark's management team and is responsible for communication and marketing to distributors, health care and other stakeholders.
Read more
Press releases

Calmark establishes cooperation with Nordic Match on Chinese expansion

Today, Calmark Sweden AB has resolved to initiate a cooperation with Nordic Match, a boutique M&A and Strategy Advisor for Sino-Nordic transactions. The cooperation covers the Chinese market entry for Calmark and the planning of a joint venture. The project will commence during summer and the expected project duration is approximately 18 months. Calmark thus advances the launch in China by about two years.
Read more
News

Calmark strengthens the team with a software developer

Calmark Sweden AB has recruited Balázs Szabó in the role of junior software developer. The employment begins on August 17.
Read more
Press releases

Calmark is developing a POC-test to help assess disease severity for patients with COVID-19 patients

The Board of Directors of Calmark Sweden AB has today resolved to develop a diagnostic point-of-care (POC) test for the lactate dehydrogenase biomarker (LDH) aimed at adult patients with COVID-19. Several studies have demonstrated that LDH levels can predict the severity and mortality of the disease. Since the time aspect of COVID-19 products is of paramount importance, this test will be developed in parallel with the tests for newborns; Neo-LDH and Neo-Glucose.
Read more
News

Calmark signs agreement regarding equipment for automation of production line

Today, Calmark Sweden AB and Automations Partner i Helsingborg Aktiebolag signed an agreement regarding the construction of the machines for the fully automated production line for the single-use tests.
Read more
News

Calmark recruits Director of International Business Development to develop global growth strategies

Calmark Sweden AB has signed an agreement with Magdalena Tharaldsen, who will be the company's new Director of International Business Development. Magdalena will be part of Calmark's Management Team and assumes responsibility for building the wide network of distributors that will provide the framework for Calmark's sales strategy.
Read more
Press releases

Calmark signs distributor agreement with Triolab regarding more markets

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Triolab Oy regarding marketing and sales of the Calmark Neo platform in Finland, Estonia, Latvia and Lithuania. Triolab already has an exclusive right to distribute Calmark's products in Sweden. The agreement means that Calmark expands its network of partners on the important domestic market.
Read more
News

The English Edition of Calmark’s Annual Report 2019 is published

Calmark Sweden AB’s Annual Report 2019 is now available also in English
Read more
Press releases

Calmark's first product, Neo-Bilirubin, obtains CE Mark

Calmark Sweden AB (publ) announces today that the product Calmark Neo-Bilirubin has obtained its CE marking in accordance with the IVD directive. The product can now be sold to and used in healthcare within the European Union.
Read more
Press releases

Calmark brings investment in production line forward

The Board of Directors of Calmark Sweden AB has today resolved to bring the final step of the automation of the production line for the single-use item forward, to build the last two steps in parallel. The Company has concluded an agreement with SEB, Skandinaviska Enskilda Banken AB (publ), relating to leasing of the production equipment.
Read more
Press releases

Calmark's trial at Södersjukhuset closed

The clinical trial with Calmark's first product, Neo-Bilirubin, which has been carried out by the research unit at the children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm, is now successfully closed with satisfactory results. Monitoring of the trial was conducted by Scandiavian CRO. The remaining step before Neo-Bilirubin can obtain its CE mark is the preparation of final reports, which is projected to take approximately two weeks.
Read more
News

Calmark's Board of Directors proposes that a new Chairman of the Board be elected by the AGM

Ahead of the Annual General Meeting, which will be held on 14 May, the Board of Directors proposes that Kjersti Berg Marthinsen be elected to replace the founder Mathias Karlsson as the Chairman of the Board of Calmark. Mathias Karlsson will remain on the board and leads the Medical Advisory Board of the Company.
Read more
Press releases

Calmark comments on the effects from COVID-19 and announces updated timetable for clinical trial at Södersjukhuset

Calmark Sweden AB announces today that the timetable for the clinical trial at Södersjukhuset with the Company's first product, Neo-Bilirubin, has been updated. All infants have still not been included, and given the current circumstances, it is difficult to predict when it will be possible to finish the study. Nevertheless, the work is progressing at the best possible pace. Once the last infant has been included, the remaining step before Neo-Bilirubin can obtain its CE mark is the preparation of final reports, which is projected to take approximately two weeks.
Read more
Press releases

Verification phase for Calmark's first product completed

The verification phase of the development project for Calmark Sweden AB's (publ) first product, Neo-Bilirubin, was completed today with successful results from all sub-phases regarding the function and performance of the product.
Read more
News

Calmark presents at Stockholm Corporate Finance 12th Life Science seminar

Calmark attends Stockholm Corporate Finance 12th Life Science Seminar that will be held at Berns on March 11 - 12, 2020. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 10:45 on March 12. The presentation is held in Swedish at Berns and will also be broadcast live at the same time.
Read more
Press releases

Market making agreement terminated - distribution requirement met

First day of trading without the liquidity guarantee is 1 April, 2020.
Read more
Press releases

Calmark signs distributor agreement with Triolab

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Triolab AB regarding marketing and distribution of the Neo Calmark platform on the Swedish market. The agreement provides Calmark with a large and well-established partner on the important domestic market.
Read more
Press releases

Updated timetable for the glucose and LDH products

Calmark Sweden AB announces today that the timetable for the development projects related to the products Neo-Glucose and Neo-LDH have been updated. These products will receive their CE conformity markings during the second quarter at the earliest, not during the first quarter as previously disclosed. The Company has prioritized its resources in order to finalize the CE marking of the first product, Neo-Bilirubin, which is projected to be achieved during the first quarter of 2020.
Read more
News

Calmark strengthens management team, recruits experienced CFO

As part of Calmark Sweden AB's continued strengthening of the organization in view of market and sales launch, Marielle Bos has been recruited for the role as CFO. Up until now, this position has been filled on an interim basis.
Read more
News

The Calmark Neo platform attracted great attention at Arab Health

During this week, Calmark Sweden AB has participated in the international healthcare and medical exhibition Arab Health in Dubai, United Arab Emirates, where the Company made contact with many prospective cooperation partners. Calmark formed the "Innovation Pavilion by Sweden" together with representatives of a total of 25 Swedish companies, organizations and authorities.
Read more
Press releases

Updated timetable for the clinical trial at Södersjukhuset

Calmark Sweden AB announces today that the timetable for the clinical trial underway at Södersjukhuset has been updated. The first patient was included on 23 December, and the rate of inclusion has thus far been lower than expected. The study is now estimated to be finished within six weeks. As a consequence, the Company's first product, Neo-Bilirubin, will obtain its CE conformity marking during the first quarter instead of in January as previously disclosed. This will not impact the market launch.
Read more
News

The Calmark Neo diagnostics platform will be showcased at the international healthcare and medical exhibition Arab Health

Calmark Sweden AB will participate in the Swedish pavilion at the large international fair Arab Health in Dubai, 27-30 January. With more than 106,000 visitors from 160 countries, Arab Health is one of the world's largest healthcare and medical trade fairs. Calmark will be there to showcase its point-of-care (POC) diagnostics platform, Calmark Neo, and to make contact with prospective customers and distributors.
Read more
Press releases

Calmark is granted design protection for the single-use item in the EU and the US

The World Intellectual Property Organization (WIPO) has announced that Calmark Sweden AB has been granted registration of the design in the EU and the US for the company’s unique single-use item.
Read more
Press releases

Calmark's Rights Issue registered – paid subscription units (BTU) are converted to shares and subscription warrants, and trading of subscription warrants commences

Calmark Sweden AB ("Calmark" or "the Company") has carried out a rights issue of units to an amount of approximately MSEK 24.1. The rights issue was completed on 29 November 2019. The rights issue resulted in subscriptions for a total value of approximately MSEK 34.6, corresponding to a subscription rate of about 142.4 percent. The rights issue is now registered with the Swedish Companies Registration Office. The last day of trading in paid subscription units (BTU) is 3 January 2020. The record date is 8 January 2020; after this day, BTU will be converted to B shares and subscription warrants. The newly issued B shares and subscription warrants are expected to be delivered to the shareholders' securities deposit/vpaccounts on 10 January 2020. Trading of subscription warrants of series TO 2 B on Spotlight Stock Market will commence on 10 January 2020.
Read more
Press releases

Significant milestone reached – product tested on patient

Today, the first patient was included in the clinical study underway at the children's hospital Sachsska barnsjukhuset, part of Södersjukhuset. For Calmark, this marks the reaching of one of the last remaining milestones for 2019, out of the ones previously disclosed.
Read more
Press releases

Calmark’s product Neo-Bilirubin will obtain CE Mark approval in January 2020

Calmark’s product for the bilirubin biomarker will obtain its CE conformity marking after the turn of the year. A partial study of the verification and validation process still remains, and the study at Södersjukhuset is not finished.
Read more
Press releases

Calmark's rights issue massively oversubscribed, provides MSEK 24.3 in total

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or “the Company”) announces today the outcome of the issue of units with preferential rights for existing shareholders, which was resolved upon by the extraordinary general meeting on 6 November 2019. The rights issue has been subscribed to an amount of approximately MSEK 34.6, which corresponds to a subscription rate of approximately 142.4 percent. This provides the Company approximately MSEK 24.3 before issuance costs which amounts to approximately 2.7 MSEK. The new issue comprises 7,366,680 B shares and 2,455,560 Series TO 2 B subscription warrants.
Read more
Press releases

Ownership change in Calmark – Creades becomes third largest owner

Creades AB (publ), a listed investment company with a net asset value of more than SEK 4 billion, have subscribed for and acquired B shares and Series TO 2 B subscription warrants in Calmark Sweden AB (publ) (“Calmark” or the “Company”) corresponding to an amount of MSEK 6.3. These transactions represent 9.44 percent of the Company's shares, which entails that Creades AB (publ) now becomes the third largest shareholder of Calmark.
Read more
Press releases

Lars Wingefors, Bengt Braun and insiders subscribe for shares in Calmark amounting in total to MSEK 9

Calmark's main owner Lars Wingefors, through the company Wingefors Invest AB, has in accordance with previous commitment and supported by unit rights, subscribed for shares amounting to MSEK 4.3 in Calmark’s preferential rights issue of MSEK 24.3. He has further subscriped for shares to an additional amount of MSEK 4.3 without support of unit rights. In addition to this, Bengt Braun together with the members of the board Stefan Blomsterberg and Anna Karin Edstedt Bonamy have subscribed for shares amounting to approximately MSEK 0.4.
Read more
Press releases

Analyst Group: Calmark Share Analysis - In the starting blocks for the global launch

Read more
Press releases

Calmark publishes information memorandum in connection with fully guaranteed rights issue

Calmark Sweden AB (publ) (“Calmark” or “the Company”) is presenting an information memorandum today, on the occasion of the rights issue of units that Calmark’s extraordinary general meeting on 6 November 2019 resolved to conduct in accordance with the Board of Directors’s proposal (“the Rights issue”). If the Rights issue is fully subscribed, the Company is initially provided approximately MSEK 24.3 before issuance costs. On full exercise of all associated subscription warrants, the Company will receive between MSEK 10.3 and MSEK 16.2 additionally, before issuance costs. The Rights issue is guaranteed through subscription commitments (68 percent, of which 50 percentage points are subscriptions with the support of unit rights and 18 percentage points are subscriptions without unit rights) and guarantee commitments (32 percent), in total corresponding to 100 percent of the initial issue amount.
Read more
News

Meet with Calmark at the international trade fair MEDICA 2019

Marianne Alksnis, International Sales Director, and Anna Söderlund, CEO of Calmark, will be present at the international medical technology trade fair MEDICA in Düsseldorf, Germany, on 18 to 21 November. Calmark will both meet with operators that have shown interest in the company and initiate discussions with prospective distributors for new markets.
Read more
Press releases

Calmark receives approval from the Swedish Ethical Review Authority to conduct clinical trial at Södersjukhuset

The Swedish Ethical Review Authority has decided to approve Calmark Sweden AB's application regarding a study on newborns. The application covers the Company’s three biomarkers and comprises three parts, which will be conducted within the next few months.
Read more
Press releases

Communiqué from the extraordinary general meeting of Calmark Sweden AB (publ)

On Wednesday, 6 November 2019, Calmark Sweden AB (publ) held an extraordinary general meeting, chaired by Mathias Karlsson. The resolutions passed are summarized below. All resolutions were passed unanimously.
Read more
Press releases

Calmark extends the time plan for CE-mark of the biomarkers LDH and Glucose - market launch as according to plan

Calmark Sweden AB (publ) announces today that the Company's products for biomarkers, LDH and glucose, will not obtain their CE conformity markings until the first quarter of 2020, the market launch of products will not be affected. The Company has focused its efforts on the first biomarker, bilirubin, whose CE-mark is on schedule, and on ramping up the production lines to facilitate market launch. As a consequence, the projects for the other biomarkers have lagged behind slightly. The update of the IVDR regulatory requirements, which will go into effect in 2022, has also had an impact, primarily on the planned clinical trials.
Read more
Press releases

Results for Calmark's initial biomarker, bilirubin, are within the expected range - project enters verification and validation phase to obtain CE mark

Calmark Sweden AB (publ) announces today that the development project for the Company's first biomarker, bilirubin, is now progressing to verification and validation. This phase, which is one of the final elements of the process, is estimated to last for approximately eight weeks. When it is completed, regulatory documentation will be compiled in order to achieve the CE Mark approval. This means that bilirubin will obtain its CE mark according to plan.
Read more
Press releases

Convocation of Extraordinary General Meeting 2019 of Calmark Sweden AB (publ)

Shareholders of Calmark Sweden AB (publ), reg.no 556696-0141 (the ”Company”), are hereby convened to an Extraordinary General Meeting on Wednesday, 6 November 2019, at 3:30 p.m., which will be held at the Company's premises, Karlstad Innovation Park, Sommargatan 101A, 656 37 Karlstad, Sweden.
Read more
Press releases

Calmark announces rights issue of 24.3 MSEK guaranteed to 100 percent and advance the date for the publication of the interim report for the third quarter

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or the “Company”) has resolved to propose a rights issue consisting of B shares and subscription warrants (units) (the “Rights issue”). The Board of Directors has therefore resolved to convene an Extraordinary General Meeting on 6 November 2019 to resolve on the Rights issue. The convocation of the Extraordinary General Meeting will be issued in a separate press release. If the Rights issue is fully subscribed, the Company is initially provided approximately MSEK 24.3 before issuance costs. On full exercise of all associated subscription warrants, the Company will receive between MSEK 10.3 and 16.2 additionally, before issuance costs. The Rights issue is guaranteed through subscription commitments of 68 per cent, of which 50 per cent are subscriptions with the support of unit rights and 18 per cent subscriptions without unit rights, as well as guarantee commitments of 32 per cent, which then in total corresponds to 100 per cent of the initial issue volume. Due to the Rights issue, the Company will advance the date for the Company's interim report for the third quarter to 13 November 2019.
Read more
News

As market launch approaches, Calmark reinforces the team with an experienced International Sales Director

Calmark Sweden AB has signed an agreement with Marianne Alksnis, who will be the company's new International Sales Director. Marianne will join the company on 15 October. She will be responsible for building the wide network of distributors that will provide the framework for Calmark's sales strategy.
Read more
Press releases

Design protection granted for Calmark's reader in Vietnam

Calmark Sweden AB has received approval for the application for industrial design right for its reader in Vietnam.
Read more
Press releases

Scientific Reports publishes a paper covering an early version of Calmark's technology

Findings from Calmark's clinical study from 2015/2016, conducted in collaboration with Södersjukhuset in Stockholm, Sweden, and Vietnam National Children’s Hospital (VNCH) in Hanoi, Vietnam, will be published in the scientific journal Scientific Reports, part of the Nature Research family. The paper is titled ”A rapid smartphone-based lactate dehydrogenase test for neonatal diagnostics at the point of care” and concludes that the point-of-care (POC) method for analysis provided reliable results within four minutes. The paper is published online on June 26.
Read more
News

Calmark has started cooperation with ShortLink regarding consultancy services in electronics

Calmark Sweden AB has started cooperation with the Karlstad-based company Shortlink AB. The cooperation regards consultancy services in electronics and development of test equipment for Calmark's reader.
Read more
Press releases

Calmark announces outcome of warrant exercise

During the period 23 May – 13 June 2019, holders of subscription warrants for Series TO 1 B in Calmark Sweden AB (publ) ("Calmark) have been entitled to subscribe for shares with warrants. A total of 2 487 202 Series TO 1 B subscription warrants were exercised, corresponding to 2 487 202 B shares and an overall exercise rate of approximately 83 percent. Calmark will thus receive approximately MSEK 13.4 in proceeds from the warrant exercises, before transaction costs of approximately MSEK 0.9. Sedermera Fondkommission has acted as financial advisor in connection with the exercise period.
Read more
News

Calmark Sweden AB signs an agreement with Scandinavian CRO regarding consulting services for clinical studies

Calmark Sweden AB has today signed an agreement with Scandinavian CRO, a Clinical Research Organization with vast experience and deep knowledge in the field of clinical studies. The agreement covers consulting services regarding the planning and execution of clinical studies on Calmark's product Neo.
Read more
Press releases

Last day of trading of Series TO 1 B subscription warrants

Today, 11 June 2019, is the last day of trading of the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)’s ("Calmark") spring/summer 2018 issue of units prior to listing. The exercise period for the Series TO 1 B subscription warrants ends on 13 June 2019.
Read more
Press releases

Reminder of the exercise of subscription warrants of Series TO 1 B

The exercise period for the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)'s ("Calmark") spring/summer 2018 issue of units prior to listing is ongoing until June 13, 2019. Last day of trading of subscription warrants of Series TO 1 B is June 11, 2019. Holders of subscription warrants for Series TO 1 B are entitled, for each warrant, to subscribe for one new B share in the company at a price of SEK 5.40 per share. On full exercise of all Series TO 1 B subscription warrants, 3 000 000 B shares will be issued and Calmark will raise approximately MSEK 16.2 before issue costs.
Read more
Press releases

Design protection granted today for Calmark's readers regarding the Indian market

Calmark Sweden AB has today received approval for the application for industrial design right for its reader in India.
Read more
Press releases

Calmark receives subscription commitments for the exercise of warrants

Today, on 27 May 2019, Calmark Sweden AB (publ) (“Calmark”) is able to announce that key persons in the Board of directors, the executive management and the main shareholders have agreed in writing to exercise their respective subscription warrants. The subscription commitments correspond to the subscription of approximately 1,581,195 shares at a price of SEK 5.40 per share, or a total amount of approximately SEK 8,538,453. This means that guaranteed undertakings corresponding to about 53 percent of the total amount that the warrants can bring now has been pre-agreed in writing. The subscription commitments have not been secured by prior transaction, bank guarantee or similar. The exercise period for the Series TO 1 B subscription warrants runs between 23 May and 13 June 2019.
Read more
Press releases

The exercise period for Series TO 1 B of Calmark’s subscription warrants begins today

Today, 23 May 2019, marks the beginning of the exercise period for the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)’s ("Calmark") spring/summer 2018 issue of units prior to listing. The exercise period runs until and including 13 June 2019. Holders of subscription warrants for Series TO 1 B are entitled, for each warrant, to subscribe for one new B share in the company at a price of SEK 5.40 per share. On full exercise of all Series TO 1 B subscription warrants, Calmark will raise approximately MSEK 16.2 before issuance costs.
Read more
News

Calmark second best IPO in 2018 in Quality category, Micro-business grade

Calmark Sweden AB (publ) receives an Honourable Mention from SvD Börsplus‘s service IPO-guiden. Calmark was the second best company in the Quality category and the fifth best in Share price development.
Read more
Press releases

Calmark and Triolab begins negotiations for distribution in the Nordic

Calmark Sweden AB (publ) announces today that negotiations for a Nordic market sales rights agreement regarding the Calmark NEO product are to be commenced with Triolab. A letter of intent has previously been signed by the parties.
Read more
Press releases

Analyst Group: Share analysis of Calmark – Market deployment around the corner

Calmark develops a point-of-care analysis method that can provide decision-making support in the care of newborns more quickly and easily than existing methods. Calmark‘s communicated goals have been achieved earlier than expected since the 2018 listing, and the company has therefore accelerated the timetable for a global market deployment. Based on a successful market deployment in 2020, combined with growth and the profitability allowed by the business model, Calmark is projected to increase net sales to approximately MSEK 67 by 2025, with an operating margin exceeding 25 percent. Taking these predictions into account and applying relative valuation, a present value per share is calculated to be SEK 8 in the base scenario.
Read more
Press releases

The English Edition of Calmark’s Annual Report 2018 is published

Calmark Sweden AB’s Annual Report 2018 is now published in English
Read more
News

Calmark's Chairman becomes Chief Medical Officer for IBM Nordic

Mathias Karlsson, Chairman of the Board and co-founder of Calmark, will take up appointment as Chief Medical Officer for IBM Nordic on May 1st. Mathias Karlsson will remain as Calmark Sweden AB‘s Chairman of the Board.
Read more
News

Calmark is nominated for Best IPO 2018

Calmark Sweden AB (publ) is nominated for the award Best IPO Company 2018 by IPO-Guiden, a service provided by SvD Börsplus.
Read more
News

Calmark recruits new interim CFO

Calmark Sweden AB has today signed an agreement with Inhouse AB, which will provide external CFO services by way of Sara Wili-Blomé. The agreement will come into force by April 1st and will run for at least six months.
Read more
Press releases

Calmark gets a patent, regarding methodology for LDH, approved in Vietnam

The Ministry of Science and Technology in Vietnam has today approved Calmark's patent application for "Test systems for the determination of hypoxia-induced cellular injury". The patent is part of Calmark's patent family regarding the methodology around the biomarker LDH and is valid until 2030.
Read more
Press releases

Decisions on a preliminary launch plan for Calmark's products for global markets have now been taken by the Board

The Board of Directors of Calmark Sweden AB has decided on a preliminary launch plan for the company's products. In the first phase, launches are taking place in the Nordic countries, the UK and Vietnam, and then increased in step two with more countries in Europe, as well as in Singapore, Malaysia and India.
Read more
Press releases

The first single-use items produced by Frohe delivered to Calmark Sweden AB

Calmark Sweden AB today received delivery of the first single-use items produced in a production environment. Frohe AB, with whom Calmark has previously signed an agreement, has produced the first single-use products.
Read more
Press releases

Prior to the forthcoming launch in Asia, Calmark today signed an agreement with Luctor Medical for consulting services.

Calmark Sweden AB has today signed an agreement with Luctor Medical in the Netherlands, an internationally leading consulting company specializing in finding distributors for medical technology products. The agreement applies to consulting services regarding distributor networks in Asia prior to the upcoming launch.
Read more
Press releases

First reader produced by Note delivered to Calmark Sweden AB

Calmark Sweden AB has today received delivery of the first reader manufactured in a production environment. Note AB in Norrtälje, with whom Calmark has previously signed an agreement, has produced the first reader.
Read more
Press releases

Calmark Sweden AB signs an agreement with Emergo by UL in the Netherlands to start registrations outside the EU area

Calmark Sweden AB has today signed an agreement with Emergo by UL, an internationally leading company in the regulatory field. The agreement concerns consulting services regarding the registration of Calmark's products in Asia prior to the coming launch.
Read more
News

Calmark builds the organization ahead of launch - strengthens the team with a Clinical Director

Calmark's introduction of the CE marking for the bilirubin test ahead of time plan, see press release from 20190121, means that the company is now entering a new phase with strengthening the organization prior to launch and sale. First out is the role of Clinical Director and today an agreement was signed with Emma Lif.
Read more
Press releases

The Bilirubin test is prioritized in Calmark's strategy for 2019, which means that launch can take place up to six months earlier than previously communicated

The Board of Directors of Calmark Sweden AB today decided to prioritize the CE marking for bilirubin test separately, before the other tests, in order to reach the market faster and get revenues earlier.
Read more
Press releases

Calmark Sweden AB signs agreement with Frohe AB to start production of the single-use items

Calmark Sweden AB has today signed an agreement with Frohe AB, a leading Swedish production partner for the manufacture of advanced plastic parts. The agreement concerns the production of Calmark's single-use products.
Read more
Press releases

Design protection granted today for Calmark's readers regarding the Chinese market

Calmark Sweden AB has today received approval from Chinese authorities for its application for industrial design right for its reader in China.
Read more
Press releases

Calmark Sweden AB signs agreement with Note AB to start production

Calmark Sweden AB has today signed an agreement with Note AB, a leading northern European manufacturing partner with an international platform for manufacturing electronic-based products. The agreement concerns the start-up of production for Calmark's reader.
Read more
Press releases

Calmark Sweden AB and Nublis AB terminate the agreement in advance

Nublis AB has delivered consulting services in finance to Calmark since April 2018. The agreement runs until the end of June 2019 but is now cancelled as of March 31, 2019.
Read more
Press releases

Calmark has achieved all important milestones for 2018

During the day, Calmark Sweden AB has achieved the last remaining milestones previously announced for 2018. The chemistry development for LDH and glucose is now ready to move on to the next step!
Read more
Press releases

Carlmark's reader approved in electrical safety testing - an important step forward in the CE marking

Today, Calmark Sweden achieved an important milestone towards the CE marking of its product NEO, when the reader passed the electrical safety testing and was approved in accordance with the applicable standard for laboratory equipment.
Read more
Press releases

Calmark is granted design protection for the reader in the EU and the US

The World Intellectual Property Organization (WIPO) has announced that Calmark Sweden AB has been granted registration of the design for the reader in the EU and the US.
Read more
Press releases

Calmark Sweden achieves important milestones in development project

Today, Calmark Sweden achieved an important milestone regarding the single-use items that enables large-scale production. The company is now leaving the prototype stage of development of the mechanics around the single-use products. In addition, resources for key functions have been secured for the company this week.
Read more
News

Newborns in the focus of new report from UNICEF

UNICEF today released a new report on child mortality in the world.
Read more
News

Calmark Sweden AB expands management team with vital skills

Calmark Sweden AB has today hired Björn Ekberg as part-time Senior RnD Member.
Read more
Press releases

The Swedish Patent and Registration Office grants important patent to Calmark Sweden AB

PRV, the Swedish patent and registration authority, announces that Calmark's patent application regarding the company's technology will be granted for Sweden on September 18, 2018. The patent's publication number will be 540 437.
Read more
News

Calmark Sweden AB extends project management collaboration with Stravus AB

Calmark Sweden AB has extended the agreement with Stravus AB until December 2019 with the possibility of extension
Read more
Press releases

Calmark Sweden AB submits two additional patent applications

Calmark Sweden AB announced that two additional patent applications are being filed as of today. The patents relate to the company's disposable product and test method for bilirubin levels. This further strengthens the company's patent protection for the market introduction of the company's products for point-of-care analyses developed for newborns.
Read more
Press releases

Calmark Sweden AB submits two additional patent applications

Calmark Sweden AB announces that two more patent applications are submitted as of today. The patent relates to the company's single-use item and the test method for bilirubin. This further strengthens the company's patent protection in preparation of the market introduction of the company's products for point-of-care analyses developed for newborns.
Read more
Press releases

Calmark Sweden AB is listed on the Spotlight Stock Market on July 6, 2018

Read more
Press releases

The first day of trading with Calmark Sweden AB's warrants is on July 6, 2018

Read more
Press releases

Calmark's issuance of units ahead of the planned listing on Spotlight fully subscribed

On June 11, 2018, the subscription period ended for Calmark Sweden AB's ("Calmark") issuance of units at an initial high of SEK 23 thousand before the company's planned listing on the Spotlight Stock Market. The issue of units was subscribed at SEK 23 thousand, including subscription commitment, corresponding to a subscription rate of approximately 100.4%. Calmark is hereby issued at SEK 23 thousand before issuance costs, which are estimated at approximately SEK 1.8. million. During issuance, Calmark acquired approximately 250 new shareholders. The first day of trading on Spotlight is expected to be July 6, 2018. Prior to the planned listing, Calmark subsequently appointed the stock brokerage firm Sedermera Fondkommission to act as liquidity guarantor for the company's series B shares. Liquidity guarantee will commence with the company's planned listing on Spotlight.
Read more